Skip to main content
Meeting Highlights
ASH Highlights, Venetoclax
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL
Phoebe Starr
Phoebe Starr, Medical Writer
Read More
Meeting Highlights
ASH Highlights, Venetoclax
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
Phoebe Starr, Medical Writer
Read More
Meeting Highlights
ASH Highlights, Immunotherapy
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
Phoebe Starr, Medical Writer
Read More
Meeting Highlights
ASH Highlights, Lymphoma
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
Phoebe Starr, Medical Writer
Read More
Meeting Highlights
ASH Highlights, Leukemia
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL
Wayne Kuznar
Wayne Kuznar, Medical Writer
Read More
FDA Updates
March 08, 2019 – FDA Approvals, News & Updates
Yvette Florio Lane
Read More
Immunotherapy, Multiple Myeloma
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
Phoebe Starr
Read More
FDA Updates
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Yvette Florio Lane
Read More
Lung Cancer
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation
Phoebe Starr
Read More
FDA Updates
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
Yvette Florio Lane
Read More
Page 156 of 200
Results 1551 - 1560 of 1993